About Aratana Therapeutics
Aratana Therapeutics is a Healthcare company based in Kansas City (United States) founded in 2010 by Steven Peter. It develops innovative small molecules and biologics for companion animal diseases. It operates on a B2B model. Aratana Therapeutics has raised $76.75 million across 5 funding rounds from investors including Square 1 Bank, Oxford Finance and Kauffman Foundation. The company has 83 employees. Its chief executive, as recorded, is Steven Peter. Its focus areas include Biotechnology, Animal Health and Therapeutics. Its legal entity is Aratana Therapeutics, Inc. Its competitors include Invetx, Gallant and Loyal; 3 of its 3 listed competitors have raised funding.
Company details
Aratana Therapeutics, founded in 2010 in Kansas City, United States, focuses on providing healthcare solutions, advancing biotech innovations, focusing on animal health, and therapeutics. Develops innovative small molecules and biologics for companion animal diseases. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
- Headquarters Kansas City, United States
- Employees 83
- Founders Steven Peter
- SectorsHealthcare
- Website aratanatherapeutics.com
- Legal Name Aratana Therapeutics, Inc.
- Total Equity Funding$76.75M (USD)
in 5 rounds
- Latest Funding Round$40M (USD), Debt – Venture
Dec 2015
- InvestorsSquare 1 Bank
& 6 more
- Employee Count83
Funding Insights of Aratana Therapeutics
Aratana Therapeutics has successfully raised a total of $76.75M across 5 strategic funding rounds. The most recent funding activity was a Debt – Venture round of $40 million completed in December 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $76.75M
- Total Rounds 5
- Last Round Debt – Venture — $40M
- First Round $20M
(Jan 2011)
- Investors Count 7
All 5 funding rounds of Aratana Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2015 | $40M | Debt – Venture | – | – | |
| Oct 2013 | $29.75M | Private Equity Round | – | – | – |
| Jan 2013 | $12M | Series C | – | – | – |
| Dec 2011 | $15M | Series B | – | – | |
| Jan 2011 | $20M | Series A | – | – |
7 investors in total: 7 institutional.
Investors in Aratana Therapeutics
Aratana Therapeutics has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Square 1 Bank, Oxford Finance and Kauffman Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
Seed and early-stage venture capital is provided to US companies. | avalon-ventures.com | Cambridge, United States | ||
| cultiviancapital.com | ||||
| kansasbioauthority.org | ||||
Venture debt, treasury, and cash management services are provided. | 2005 | square1bank.com | Durham, United States | |
Invests in biotech firms developing life-saving drugs and technologies. | mpmcapital.com | |||
Funding is provided for education, workforce, and entrepreneurship initiatives. | 1966 | kauffman.org | Kansas City, United States |
Investor details for Aratana Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Aratana Therapeutics
1 people are tracked at Aratana Therapeutics (1 in leadership); the tracked headcount is 83.
| Name | Role | Group |
|---|---|---|
Steven Peter | Founder, President, CEO | Leadership |
Complete people profiles for Aratana Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Aratana Therapeutics
3 dated milestones of Aratana Therapeutics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Aratana Therapeutics is founded.
- Funding First funding round of $20.0M.
- Funding Latest funding round, Debt – Venture, of $40.0M.
Competitors of Aratana Therapeutics
Aratana Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Invetx, Gallant and Loyal.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| invetx.com | 2018 | Boston, United States | $86M | Provider of pharmaceutical products like protein-based therapeutics for pets | ||
| gallant.com | 2018 | Los Angeles, United States | $61.46M | Stem cell storage for canine regenerative therapy is offered. | ||
| loyal.app | 2020 | Encinitas, United States | $31.97M | Mobile application development, data management, and advertising services are provided. |
Detailed competitors of Aratana Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Aratana Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Aratana Therapeutics
Aratana Therapeutics was founded in 2010 and raised its 1st funding round 1 year after it was founded.
Aratana Therapeutics is headquartered in Kansas City, United States. It is registered at Kansas City, Missouri, United States.
Steven Peter is the CEO of Aratana Therapeutics, as recorded in our data. They have also founded this company.
Aratana Therapeutics is a funded company, having raised a total of $76.75M across 5 funding rounds to date. The company's 1st funding round was a Series A of $20M, raised on Jan 2011.
Aratana Therapeutics has 83 employees.
Aratana Therapeutics, founded in 2010 in Kansas City, United States, focuses on providing healthcare solutions, advancing biotech innovations, focusing on animal health, and therapeutics. Develops innovative small molecules and biologics for companion animal diseases. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
Aratana Therapeutics has 7 investors. Key investors include Square 1 Bank, Oxford Finance, Kauffman Foundation, Turmeric Acquisition Corp, and Avalon Ventures.
Aratana Therapeutics operates through Aratana Therapeutics, Inc..